Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07411560 | A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese | PHASE1 | RECRUITING | 100 | — | — | Feb 9, 2026 | Jan 26, 2027 | Apr 13, 2026 | 1 | United Kingdom |
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| Arm 1:Glucose dependent Insulinotropic Polypeptide(GIP)+Cagrilintide then Placebo GIP+Cagrilintide | EXPERIMENTAL | Participants will receive low dose of GIP and Cagrilintide escalated to medium dose of GIP and high dose of Cagrilintide in treatment period 1 followed by GIP Placebo along with escalating doses of Cagrilintide from low to high in treatment period 2. |
| Arm 2: Placebo GIP + Cagrilintide then GIP + Cagrilintide | EXPERIMENTAL | Participants will receive GIP placebo along with escalating doses of Cagrilintide from low to high in treatment period 1 followed by low dose of GIP and Cagrilintide escalated to medium dose of GIP and high dose of Cagrilintide in treatment period 2. |
| Arm 3: GIP + Cagrilintide then Placebo GIP + Cagrilintide | EXPERIMENTAL | Participants will receive high dose of GIP and low dose of Cagrilintide escalated to higher dose of GIP and high dose of Cagrilintide in treatment period 1 followed by GIP Placebo along with escalating doses of Cagrilintide from low to high in treatment period 2. |
| Arm 4: Placebo GIP + Cagrilintide then GIP + Cagrilintide | EXPERIMENTAL | Participants will receive GIP placebo along with escalating doses of Cagrilintide from low to high in treatment period 1 followed by medium dose of GIP and low dose of Cagrilintide escalated to higher dose of GIP and high dose of Cagrilintide in treatment period 2. |
| Name | Type | Description |
|---|---|---|
| Glucose-dependent Insulinotropic Polypeptide (GIP) | DRUG | Participants will receive GIP subcutaneously. |
| Cagrilintide | DRUG | Participants will receive Cagrilintide subcutaneously. |
| Placebo GIP | DRUG | Participants will receive placebo matched to GIP subcutaneously. |
Inclusion Criteria: * Female at birth. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 27.0 kilograms per square meter (kg/m\^2) and 39.9 kg/m\^2 (both inclusive) at screening. * Overweight should be due to excess adipose tissue, as ju...